Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 667 results for diabetes

  1. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

  2. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

  3. Backing the healthtech that changes lives

    NICE-recommended healthtech, including a hybrid closed loop system for type 1 diabetes, an implantable cardiac monitor to detect atrial...

  4. What is the most effective management strategy for preventing the development of excessive weight gain and metabolic syndrome associated with the use of antipsychotic medication in children and young people?

    and poor physical health (smoking, lack of exercise) leading to type 2 diabetes and metabolic syndrome are major sources of morbidity...

  5. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

  6. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  7. VA ECMO for severe acute heart failure in adults (HTG764)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  8. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  9. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    aids)• comorbidities (chronic obstructive pulmonary disease, hypertension, diabetes, coronary heart disease, chronic kidney disease,...

  10. Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section (HTG380)

    Evidence-based recommendations on insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. The catheter aims to help induction by causing dilation of the cervix when the cervix is unfavourable for induction. The double balloon squeezes the cervix and stimulates local prostaglandin release, which leads to cervical ripening.

  11. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  12. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  13. Antenatal and postnatal mental health: clinical management and service guidance (CG192)

    This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.

  14. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  15. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making